HDAC inhibition induces microRNA-182 which targets Rad51 and impairs HR repair to sensitize cells to sapacitabine in acute myelogenous leukemia

Autor Lai, Tsung-Huei, Ewald, Brett, Zecevic, Alma, Liu, Chaomei, Sulda, Melanie, Papaioannou, Dimitrios, Garzon, Ramiro, Blachly, J.S, Plunkett, William, Sampath, Deepa
Vydáno v Clin Cancer Res (2016)

Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3)

Autor Bhatnagar, B, Blachly, JS, Kohlschmidt, J, Eisfeld, A-K, Volinia, S, Nicolet, D, Carroll, AJ, Block, AW, Kolitz, JE, Stone, RM, Mrózek, K, Byrd, JC, Bloomfield, CD
Vydáno v Leukemia (2015)

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

Autor Woyach, J.A., Ruppert, A.S., Heerema, N.A., Zhao, W., Booth, A.M., Ding, W., Bartlett, N.L., Brander, D.M., Barr, P.M., Rogers, K.A., Parikh, S.A., Coutre, S., Hurria, A., Brown, J.R., Lozanski, G., Blachly, J.S., Ozer, H.G., Major-Elechi, B., Fruth, B., Nattam, S., Larson, R.A., Erba, H., Litzow, M., Owen, C., Kuzma, C., Abramson, J.S., Little, R.F., Smith, S.E., Stone, R.M., Mandrekar, S.J., Byrd, J.C.
Vydáno v N Engl J Med (2018)

EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia

Autor Young, E, Noerenberg, D, Mansouri, L, Ljungström, V, Frick, M, Sutton, L-A, Blakemore, SJ, Galan-Sousa, J, Plevova, K, Baliakas, P, Rossi, D, Clifford, R, Roos-Weil, D, Navrkalova, V, Dörken, B, Schmitt, CA, Smedby, KE, Juliusson, G, Giacopelli, B, Blachly, JS, Belessi, C, Panagiotidis, P, Chiorazzi, N, Davi, F, Langerak, AW, Oscier, D, Schuh, A, Gaidano, G, Ghia, P, Xu, W, Fan, L, Bernard, OA, Nguyen-Khac, F, Rassenti, L, Li, J, Kipps, TJ, Stamatopoulos, K, Pospisilova, S, Zenz, T, Oakes, CC, Strefford, JC, Rosenquist, R, Damm, F
Vydáno v Leukemia (2016)